While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...
A 2-point improvement in pain based on a numeric rating scale may indicate that patients are responding to treatment for pyoderma gangrenosum. To help determine whether a patient with pyoderma ...
Please provide your email address to receive an email when new articles are posted on . Patients with pyoderma gangrenosum are at greater risk of all-cause and cause-specific mortality compared with ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Ulcerative pyoderma gangrenosum is a rare disease with ...
JENA, Germany, May 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that ...
InflaRx ( (IFRX)) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma gangrenosum (PG), a rare, difficult-to-treat ulcerative ...
In a recently published systematic review, researchers determined that VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome typically presents in men, with atypical morphology and ...
Backers of Jena, Germany-based Inflarx NV have turned their attention to the rest of the pipeline after the stock-jolting news from an independent data monitoring committee (DMC) responsible for the ...
While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results